Provided By Business Wire
Last update: Apr 18, 2025
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
The release was issued in error by Aditxt, Inc.
A replacement release will not be issued at this time.
NASDAQ:ADTX (4/22/2025, 2:02:55 PM)
2.26
+0.03 (+1.35%)
Find more stocks in the Stock Screener